Accepted for Publication: August 9, 2021.
Published: October 15, 2021. doi:10.1001/jamanetworkopen.2021.28806
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Ortiz AP et al. JAMA Network Open.
Corresponding Author: Ana Patricia Ortiz, PhD, University of Puerto Rico Comprehensive Cancer Center, PO Box 363027, San Juan, PR 00936-3027 (ana.ortiz7@upr.edu).
Author Contributions: Dr Ortiz-Ortiz and Mr Gierbolini-Bermúdez had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Ortiz, Ramos-Cartagena, Deshmukh.
Acquisition, analysis, or interpretation of data: Ortiz, Gierbolini-Bermúdez, Colón-López, Sonawane, Deshmukh, Ortiz-Ortiz.
Drafting of the manuscript: Ortiz, Ramos-Cartagena, Colón-López, Deshmukh.
Critical revision of the manuscript for important intellectual content: Ortiz, Gierbolini-Bermúdez, Ramos-Cartagena, Sonawane, Deshmukh, Ortiz-Ortiz.
Statistical analysis: Gierbolini-Bermúdez, Sonawane, Deshmukh, Ortiz-Ortiz.
Obtained funding: Ortiz, Colón-López, Deshmukh.
Administrative, technical, or material support: Ortiz, Colón-López, Deshmukh.
Supervision: Ortiz, Colón-López.
Conflict of Interest Disclosures: Dr Ortiz reported receiving grants from the National Institutes of Health during the conduct of the study, and reported consulting fees from Merck & Co outside the submitted work. Dr Ortiz-Ortiz reported receiving grants from the Centers for Disease Control and Prevention National Program of Cancer Registries and the National Cancer Institute during the conduct of the study, and reported grants from Abbvie Corp outside the submitted work. Dr Colón-López reported receiving consulting fees from Merck & Co outside the submitted work. Dr Ortiz-Ortiz reported receiving grants from Abbvie Corp and Merck & Co outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by a National Cancer Institute U54 Grant (No. 2U54CA096297-18). The Puerto Rico Health Insurance Administration provided data for this study.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
2.Ortiz
AP , Calo
WA , Mendez-Lazaro
P ,
et al. Strengthening resilience and adaptive capacity to disasters in cancer control plans: lessons learned from Puerto Rico.
Cancer Epidemiol Biomarkers Prev. 2020;29(7):1290-1293. doi:
10.1158/1055-9965.EPI-19-1067PubMedGoogle Scholar 5.Miller
MJ , Xu
L , Qin
J ,
et al. Impact of COVID-19 on cervical cancer screening rates among women aged 21-65 years in a large integrated health care system—Southern California, January 1-September 30, 2019, and January 1-September 30, 2020.
MMWR Morb Mortal Wkly Rep. 2021;70(4):109-113. doi:
10.15585/mmwr.mm7004a1PubMedGoogle Scholar 6.Shing
JZ , Griffin
MR , Nguyen
LD ,
et al. Improving cervical precancer surveillance: validity of claims-based prediction models in
ICD-9 and
ICD-10 eras.
JNCI Cancer Spectr. 2020;5(1):a112. doi:
10.1093/jncics/pkaa112PubMedGoogle Scholar